Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168272 | 0.89 | TDP1 (0.59) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL8062203 | 0.89 | TDP1 (0.59) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL10190369 | 0.89 | TDP1 (0.59) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL13040189 | 0.87 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL8042680 | 0.87 | TDP1 (0.51) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL4811672 | 0.87 | MEN1 (0.50) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL24177101 | 0.86 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL2296898 | 0.85 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL28323890 | 0.85 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACA1 | |
| SCHEMBL2296899 | 0.85 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163541-A1 | Method for Preparing PNA Oligomer | SEASUNBIO MATERIALS (KR) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163541-A1 | Method for Preparing PNA Oligomer | NCL, NOD1, POLI | TDP1 775/4885MEN1 2705/4885GAA 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.